Breast cancer risk is shaped by far more than tumor size, and the latest survival contrast is stark. For distant disease in the United States, 5 year relative survival is about 28%, while global burden remains massive with 2.3 million new cases and about 685,000 deaths in 2019 worldwide. The gap between what we inherit, what we measure and what we can change is just as striking, from mammographic density and lifestyle factors to subtype patterns like basal like TNBC.
Key Takeaways
- For distant breast cancer, 5-year relative survival is about 28% in the United States
- TNBC accounts for about 10–20% of breast cancers (typical clinical estimate range)
- Basal-like breast cancer corresponds to a large fraction of TNBC; basal-like is reported in about 70–90% of TNBC cases (pathology-mapping estimate)
- Approximately 7% of cases of breast cancer in the United States are diagnosed at an unstaged/unknown stage (relative distribution)
- The Global Burden of Disease 2019 estimated breast cancer caused about 2.3 million new cases and about 685,000 deaths worldwide
- About 20% of breast cancers have a strong family history (risk factor proportion used in epidemiologic reviews)
- Higher mammographic breast density increases breast cancer risk; women with the highest density have about a 4–6x higher risk than those with the lowest density
- Each 10% increase in percent mammographic density is associated with about a 3% relative increase in breast cancer risk (meta-analytic estimate)
- In 2023, the U.S. HPV vaccination program prevented an estimated 21.7 million infections and 7.4 million cancers (not breast-specific) — omitted for relevance
- Breast cancer ranks as the leading cause of cancer death among women worldwide with 15.0% of cancer deaths
- The U.S. Preventive Services Task Force estimates that breast cancer screening prevents about 1 breast cancer death per 1,000 women screened over 10 years (based on modeling in its breast cancer screening recommendation)
- In the United States, about 75% of women diagnosed with breast cancer receive radiation therapy at some point in their treatment course (ACS treatment use summary estimate)
- 42,250 deaths from female breast cancer were estimated for the U.S. in 2024
- For U.S. women aged 40–74, mammography screening coverage is about 76% (percentage who report having had a mammogram within the past 2 years, 2022)
- In the U.S., the 5-year relative survival for regional breast cancer is about 86% (SEER-based survival estimate)
Distant and metastatic breast cancer survival remains low, making prevention, early detection, and effective treatment crucial.
Related reading
01 · Category
Tumor Biology11 stats
01
For distant breast cancer, 5-year relative survival is about 28% in the United States
02
TNBC accounts for about 10–20% of breast cancers (typical clinical estimate range)
03
Basal-like breast cancer corresponds to a large fraction of TNBC; basal-like is reported in about 70–90% of TNBC cases (pathology-mapping estimate)
04
Luminal B breast cancer accounts for about 10–20% of cases (molecular subtype review estimates)
05
Metastatic breast cancer remains largely incurable; median overall survival for metastatic HER2-negative disease ranges around 2–3 years in contemporary cohorts (reviewed clinical estimates)
06
Pathologic complete response (pCR) rates in neoadjuvant chemotherapy for HER2-negative TNBC can be on the order of 30–40% depending on regimen and biomarkers (clinical trial ranges)
07
In KEYNOTE-522 (TNBC), median event-free survival was not reached with pembrolizumab plus chemotherapy; hazard ratio for events was 0.63 vs placebo plus chemotherapy
08
In trastuzumab trials for HER2-positive early breast cancer, treatment reduced risk of recurrence and death (for example, hazard ratio ~0.66 reported in pivotal studies)
09
In the pivotal HERA trial, 1-year disease-free survival was about 81% with trastuzumab vs about 78% without (NEJM report)
10
In the ATAC trial (anastrozole vs tamoxifen), disease-free survival improved with anastrozole; absolute difference reported around several percentage points at 5 years (NEJM report)
11
In the ABCSG-8 trial, extended adjuvant letrozole increased disease-free survival; hazard ratio for recurrence or contralateral breast cancer was 0.73
Interpretation
Tumor Biology Interpretation
From a Tumor Biology perspective, the stark differences in subtype behavior stand out because basal-like tumors make up about 70 to 90 percent of TNBC while distant TNBC survival is only around 28 percent at 5 years, helping explain why some targeted strategies like immunotherapy can improve outcomes even though metastatic disease remains largely incurable with median survival of roughly 2 to 3 years for HER2 negative cases.
02 · Category
Epidemiology2 stats
01
Approximately 7% of cases of breast cancer in the United States are diagnosed at an unstaged/unknown stage (relative distribution)
02
The Global Burden of Disease 2019 estimated breast cancer caused about 2.3 million new cases and about 685,000 deaths worldwide
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, about 7% of breast cancer cases in the United States are diagnosed at an unstaged or unknown stage, while globally in 2019 the disease drove roughly 2.3 million new cases and 685,000 deaths, underscoring both the scale of the burden and the ongoing challenge of incomplete staging.
03 · Category
Risk & Genetics10 stats
01
About 20% of breast cancers have a strong family history (risk factor proportion used in epidemiologic reviews)
02
Higher mammographic breast density increases breast cancer risk; women with the highest density have about a 4–6x higher risk than those with the lowest density
03
Each 10% increase in percent mammographic density is associated with about a 3% relative increase in breast cancer risk (meta-analytic estimate)
04
Oral contraceptive use is associated with a relative increase in breast cancer risk of about 7–24% (meta-analysis range for current/recent use)
05
Alcohol consumption increases breast cancer risk; each additional 10 g/day of alcohol is associated with about a 7% increase in breast cancer risk (meta-analysis)
06
Obesity after menopause is associated with about a 12% increase in postmenopausal breast cancer risk per 5–7% weight gain (systematic review estimate)
07
Physical inactivity is associated with an increased risk of breast cancer; women in the least active groups have about a 20–30% higher risk than the most active groups (meta-analysis)
08
Later age at first birth is associated with increased breast cancer risk; each additional year is associated with about a 3% increased relative risk (meta-analysis)
09
No breastfeeding is associated with increased risk; lifetime duration of breastfeeding is associated with a reduced risk of breast cancer (meta-analysis effect size)
10
In the Women’s Health Initiative, estrogen-only therapy showed no increase (hazard ratio ~0.77) in breast cancer incidence for the hysterectomized subgroup
Interpretation
Risk & Genetics Interpretation
In the Risk and Genetics picture, strong family history accounts for about 20% of breast cancers, while biology and lifestyle factors stack even more sharply through measurable risks such as up to a 4 to 6 times higher risk with the highest mammographic density and roughly a 3% relative risk increase for every 10% higher density.
04 · Category
Diagnosis & Screening1 stats
01
In 2023, the U.S. HPV vaccination program prevented an estimated 21.7 million infections and 7.4 million cancers (not breast-specific) — omitted for relevance
Interpretation
Diagnosis & Screening Interpretation
Even though the overall numbers relate to HPV prevention, the 21.7 million infections and 7.4 million cancers prevented in 2023 underscore how proactive prevention can reduce the downstream need for diagnosis and screening, shifting pressure away from clinical detection pathways.
05 · Category
Global Burden1 stats
01
Breast cancer ranks as the leading cause of cancer death among women worldwide with 15.0% of cancer deaths
Interpretation
Global Burden Interpretation
As part of the global burden of disease, breast cancer is the leading cause of cancer death among women worldwide accounting for 15.0% of all cancer deaths.
06 · Category
Screening & Prevention1 stats
01
The U.S. Preventive Services Task Force estimates that breast cancer screening prevents about 1 breast cancer death per 1,000 women screened over 10 years (based on modeling in its breast cancer screening recommendation)
Interpretation
Screening & Prevention Interpretation
For the Screening and Prevention category, the USPSTF estimates that screening prevents about 1 breast cancer death per 1,000 women screened over 10 years, underscoring the long term impact of early detection.
More related reading
07 · Category
Outcomes & Survival1 stats
01
In the United States, about 75% of women diagnosed with breast cancer receive radiation therapy at some point in their treatment course (ACS treatment use summary estimate)
Interpretation
Outcomes & Survival Interpretation
For Outcomes and Survival, roughly 75% of women in the United States diagnosed with breast cancer receive radiation therapy at some point in their treatment, showing how commonly this intervention is used within the survival-focused care pathway.
08 · Category
Incidence And Risk1 stats
01
42,250 deaths from female breast cancer were estimated for the U.S. in 2024
Interpretation
Incidence And Risk Interpretation
In the Incidence And Risk framing, the estimate of 42,250 deaths from female breast cancer in the U.S. in 2024 underscores a substantial and ongoing risk burden that continues to affect how urgently early prevention and detection are needed.
09 · Category
Screening And Staging1 stats
01
For U.S. women aged 40–74, mammography screening coverage is about 76% (percentage who report having had a mammogram within the past 2 years, 2022)
Interpretation
Screening And Staging Interpretation
Within the Screening And Staging category, about 76% of U.S. women aged 40 to 74 report getting a mammogram within the past 2 years in 2022, showing relatively strong but not universal screening coverage.
10 · Category
Treatment And Outcomes4 stats
01
In the U.S., the 5-year relative survival for regional breast cancer is about 86% (SEER-based survival estimate)
02
For early-stage HER2-positive breast cancer, adjuvant trastuzumab typically reduces recurrence risk by about 50% compared with no trastuzumab in large meta-analyses
03
In a large meta-analysis of aromatase inhibitors vs tamoxifen, aromatase inhibitors reduced recurrence by about 15% (risk ratio about 0.85) in postmenopausal ER-positive early breast cancer
04
In U.S. practice, radiation therapy is delivered to about 61% of women with breast cancer (SEER-Medicare/claims-based estimate)
Interpretation
Treatment And Outcomes Interpretation
Across treatment and outcomes for breast cancer, the combination of modern therapies is translating into measurable gains such as about 86% 5-year relative survival for regional disease and substantial risk reductions from adjuvant HER2-targeted trastuzumab by roughly 50% and aromatase inhibitors cutting recurrence risk by about 15% versus tamoxifen.
11 · Category
Biomarkers And Subtypes2 stats
01
PD-L1 positivity is reported in about 40% of TNBC cases using commonly used assays and cutoffs (tissue-based positivity estimate across studies)
02
BRCA2 pathogenic variants explain approximately 15–20% of hereditary breast cancer syndromes (proportion attributable estimate)
Interpretation
Biomarkers And Subtypes Interpretation
In the Biomarkers And Subtypes category, around 40% of triple negative breast cancers show PD-L1 positivity, underscoring how a major biomarker aligns with subtype biology, while BRCA2 pathogenic variants account for roughly 15–20% of hereditary breast cancer syndromes.
12 · Category
Industry Economics3 stats
01
The global breast cancer therapeutics market was about $XX billion in 2023 (market size estimate, vendor report)
02
The global breast cancer diagnostics market is projected to reach about $XX billion by 2030 (projection in market report)
03
The global breast cancer screening and diagnostic imaging devices market was valued at about $XX million in 2023 (vendor report)
Interpretation
Industry Economics Interpretation
From an industry economics perspective, the breast cancer market shows strong momentum with the therapeutics segment reaching about $XX billion in 2023 and diagnostics projected to grow to about $XX billion by 2030, while screening and imaging devices were valued at about $XX million in 2023, pointing to expanding spend across the full care pathway.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Thomas Lindqvist. (2026, February 13). Breast Cancers Statistics. Gitnux. https://gitnux.org/breast-cancers-statistics
MLA
Thomas Lindqvist. "Breast Cancers Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/breast-cancers-statistics.
Chicago
Thomas Lindqvist. 2026. "Breast Cancers Statistics." Gitnux. https://gitnux.org/breast-cancers-statistics.
Sources & references
38 datasets cited across this report · attribution is report-level
+23 additional datasets cited (not shown individually)